DK3023788T3 - Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer - Google Patents

Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer Download PDF

Info

Publication number
DK3023788T3
DK3023788T3 DK15198284.0T DK15198284T DK3023788T3 DK 3023788 T3 DK3023788 T3 DK 3023788T3 DK 15198284 T DK15198284 T DK 15198284T DK 3023788 T3 DK3023788 T3 DK 3023788T3
Authority
DK
Denmark
Prior art keywords
tumors
tumor
compositions
treatment
specific neoantigens
Prior art date
Application number
DK15198284.0T
Other languages
Danish (da)
English (en)
Inventor
Nir Hacohen
Catherine Wu
Original Assignee
Massachusetts Gen Hospital
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44915022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3023788(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Gen Hospital, Dana Farber Cancer Inst Inc filed Critical Massachusetts Gen Hospital
Application granted granted Critical
Publication of DK3023788T3 publication Critical patent/DK3023788T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK15198284.0T 2010-05-14 2011-05-16 Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer DK3023788T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33486610P 2010-05-14 2010-05-14
EP11781409.5A EP2569633B1 (en) 2010-05-14 2011-05-16 Compositions and methods of identifying tumor specific neoantigens

Publications (1)

Publication Number Publication Date
DK3023788T3 true DK3023788T3 (da) 2020-04-27

Family

ID=44915022

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15198284.0T DK3023788T3 (da) 2010-05-14 2011-05-16 Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer

Country Status (14)

Country Link
US (8) US9115402B2 (enExample)
EP (4) EP2569633B1 (enExample)
JP (5) JP5948319B2 (enExample)
KR (4) KR102447139B1 (enExample)
CN (2) CN103180730B (enExample)
AU (1) AU2011252795B2 (enExample)
BR (2) BR122021014039B1 (enExample)
CA (2) CA3197245A1 (enExample)
DK (1) DK3023788T3 (enExample)
ES (3) ES2788863T3 (enExample)
HU (1) HUE049886T2 (enExample)
PL (1) PL3023788T3 (enExample)
PT (1) PT3023788T (enExample)
WO (1) WO2011143656A2 (enExample)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
LT2714071T (lt) * 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
SI2714071T1 (sl) * 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizirana cepiva proti raku
EP2757153B1 (en) * 2011-08-02 2019-07-03 The University of Tokyo Method for assessing myelodysplastic syndrome or myeloid tumor predisposition, polypeptide and antibody therefor, and candidate screening method for therapeutic drug or prophylactic drug therefor
US20130164746A1 (en) * 2011-09-29 2013-06-27 Davide Rossi Mutations in SF3B1 and Chronic Lymphocytic Leukemia
WO2013086464A1 (en) * 2011-12-07 2013-06-13 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2013177593A2 (en) 2012-05-25 2013-11-28 Phosimmune, Inc. Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
WO2014036562A2 (en) * 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
HK1212236A1 (en) 2012-09-05 2016-06-10 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
US10501801B2 (en) 2012-09-28 2019-12-10 University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP3578200A1 (en) 2013-02-22 2019-12-11 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
MX376790B (es) 2013-03-14 2025-03-07 Univ Johns Hopkins Células presentadoras de antígeno artificiales de nanoescala.
AU2014251207B2 (en) * 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP6740127B2 (ja) * 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
SG11201605432RA (en) * 2014-01-02 2016-07-28 Sloan Kettering Inst Cancer Determinants of cancer response to immunotherapy
CA2935878C (en) 2014-03-12 2023-05-02 Curevac Ag Combination of vaccination and ox40 agonists
EP3137100B1 (en) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
US20170224799A1 (en) * 2014-09-10 2017-08-10 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
EP3194970B1 (en) * 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
CA2961179A1 (en) * 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
SG11201702191YA (en) * 2014-09-17 2017-04-27 Univ Johns Hopkins Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
PL3193917T3 (pl) * 2014-09-17 2022-01-17 Io Biotech Aps Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
CN107075479A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
CA2964155A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
AU2016238290B9 (en) 2015-03-25 2019-06-13 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
CA3172682A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
MX381241B (es) * 2015-04-27 2025-03-12 Cancer Research Tech Ltd Composición de células t para usarse en el tratamiento del cáncer.
US10544392B2 (en) 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
EP3294324A1 (en) 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
JP6913032B2 (ja) * 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
US10563266B2 (en) 2015-07-14 2020-02-18 Personal Genome Diagnostics Inc. Neoantigen treatment prioritization using multivariate analysis based on: HLA genotype, self-similarity, similarity to known antigens, antigen expression levels and mutant allele frequency
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
US11167024B2 (en) * 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
KR20180087246A (ko) * 2015-10-12 2018-08-01 난토믹스, 엘엘씨 네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법
WO2017066290A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Viral neoepitopes and uses thereof
AU2016339035A1 (en) * 2015-10-12 2018-05-10 Nantomics, Llc Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors
CN108601820A (zh) * 2015-10-12 2018-09-28 南托米克斯有限责任公司 用于病毒癌症新表位的组合物和方法
EP3364949A4 (en) * 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
MX2018004838A (es) 2015-11-06 2019-07-18 Ventana Med Syst Inc Diagnosticos representativos.
TWI733719B (zh) * 2015-12-07 2021-07-21 美商河谷控股Ｉｐ有限責任公司 改善的組合物及用於新表位之病毒遞送的方法及其應用
JP7114477B2 (ja) * 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
CA3048202A1 (en) * 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by inhibition of nonsense mediated decay
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CN108701172A (zh) * 2016-02-12 2018-10-23 南托米克斯有限责任公司 高通量识别患者特异性新表位作为癌症免疫疗法的治疗靶点
AU2017219901B2 (en) * 2016-02-19 2022-07-14 Nant Holdings Ip, Llc Methods of immunogenic modulation
CN105720176A (zh) * 2016-02-19 2016-06-29 京东方科技集团股份有限公司 一种胶囊量子点和发光二极管、制备方法及显示装置
JP2019513021A (ja) * 2016-03-24 2019-05-23 ナントセル，インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
WO2017180769A1 (en) * 2016-04-13 2017-10-19 Capten Therapeutics Inc. Small molecules for immunogenic treatment of cancer
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
US20190247435A1 (en) * 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CA3031003A1 (en) * 2016-07-20 2018-01-25 Biontech Rna Pharmaceuticals Gmbh Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
AU2017305396A1 (en) * 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
US10350280B2 (en) 2016-08-31 2019-07-16 Medgenome Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
US20190237158A1 (en) * 2016-08-31 2019-08-01 Medgenome, Inc. Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment
EP3516045A1 (en) * 2016-09-23 2019-07-31 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
US20190240257A1 (en) * 2016-10-13 2019-08-08 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
EP4338799A3 (en) * 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
US20190321481A1 (en) 2016-11-11 2019-10-24 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
WO2018102613A2 (en) 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3052255A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
EP3601536A4 (en) * 2017-03-20 2021-01-13 Genocea Biosciences, Inc. TREATMENT PROCEDURES
WO2018183544A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Method for identification of retained intron tumor neoantigens from patient transcriptome
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
JP2020515629A (ja) 2017-04-04 2020-05-28 アヴィディア テクノロジーズ， インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
AU2018254526B2 (en) * 2017-04-19 2024-02-15 Seattle Project Corp. Neoantigen identification, manufacture, and use
CA3061240C (en) 2017-04-24 2024-01-16 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
EP3622068B1 (en) 2017-05-10 2024-02-28 The Broad Institute, Inc. Methods for determination of mutations in single replication events
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
EP3630131B1 (en) * 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized canine cancer vaccines
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
KR20240113607A (ko) * 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
KR20200030593A (ko) 2017-07-21 2020-03-20 버클리 라잇츠, 인크. 항원 제시 합성 표면, 공유결합으로 관능화된 표면, 활성화된 t 세포, 및 이들의 용도
CN111727262A (zh) 2017-07-25 2020-09-29 加州理工学院 胞啃介导的表位发现
WO2019036043A2 (en) * 2017-08-16 2019-02-21 Medgenome Inc. METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
CA3076918A1 (en) * 2017-10-02 2019-04-11 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
RU2020115161A (ru) * 2017-10-06 2021-11-08 Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи Днк моноклональных антител против ctla-4 для лечения и профилактики рака
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
CA3081479A1 (en) * 2017-11-06 2019-05-09 Ludwig Institute For Cancer Research Ltd Method for expansion of lymphocytes
WO2019094396A1 (en) * 2017-11-07 2019-05-16 Nektar Therapeutics Immunotherapeutic combination for treating cancer
JP7054418B2 (ja) 2017-11-08 2022-04-13 ビオンテック ユーエス インコーポレイテッド Ｔ細胞を製造する組成物及び方法
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
CN109682978B (zh) * 2017-11-30 2020-07-03 四川康德赛医疗科技有限公司 一种肿瘤突变肽mhc亲和力预测方法及其应用
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
KR20240134250A (ko) 2018-01-04 2024-09-06 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
US11573230B2 (en) 2018-01-26 2023-02-07 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
EP3743102A1 (en) 2018-01-26 2020-12-02 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
IL276839B1 (en) * 2018-02-27 2026-05-01 Gritstone Bio Inc Neoantigen identification using pan-allelic models
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
TW202000907A (zh) 2018-05-23 2020-01-01 美商葛利史東腫瘤科技公司 共有抗原
US12528848B2 (en) 2018-05-25 2026-01-20 The Wistar Institute Of Anatomy And Biology Tumor-specific neoantigens and methods of using the same
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
CA3106567A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
WO2020022901A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
CA3106574A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
CA3106573A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
WO2020022897A1 (en) * 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
JP7539367B2 (ja) 2018-08-31 2024-08-23 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
KR20210063362A (ko) 2018-09-21 2021-06-01 버클리 라잇츠, 인크. 작용화된 웰 플레이트, 이의 제조 및 사용 방법
BR112021005702A8 (pt) 2018-09-27 2022-11-08 Vaccibody As Método para selecionar neoepítopos
WO2020081875A1 (en) 2018-10-18 2020-04-23 Berkeley Lights, Inc. Proto-antigen-presenting synthetic surfaces, activated t cells, and uses thereof
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
JP7863702B2 (ja) 2018-11-08 2026-05-22 セルキュア インコーポレイテッド 表現型特性が向上したｔ細胞組成物
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN109706065A (zh) * 2018-12-29 2019-05-03 深圳裕策生物科技有限公司 肿瘤新生抗原负荷检测装置及存储介质
JP2022521738A (ja) 2019-02-20 2022-04-12 ルビウス セラピューティクス， インコーポレイテッド 負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
US12427195B1 (en) * 2019-03-11 2025-09-30 La Jolla Institute For Immunology Methods of neoantigen identification
US20220130489A1 (en) * 2019-03-12 2022-04-28 Syntekabio,Inc. System and method for providing neoantigen immunotherapy information by using artificial-intelligence-model-based molecular dynamics big data
WO2020227233A2 (en) * 2019-05-03 2020-11-12 Richard Guilhem Neoantigens in cancer
EP3966323A4 (en) * 2019-05-06 2024-04-24 The Regents Of The University Of Michigan Targeted therapy
TWI867324B (zh) 2019-05-08 2024-12-21 美商百歐恩泰美國公司 T細胞製備組合物及方法
CN112011833B (zh) * 2019-05-30 2024-04-26 上海桀蒙生物技术有限公司 筛选和分离肿瘤新生抗原的方法
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
CN110322925B (zh) * 2019-07-18 2021-09-03 杭州纽安津生物科技有限公司 一种预测融合基因产生新生抗原的方法
CN110706747B (zh) * 2019-09-17 2021-09-07 北京橡鑫生物科技有限公司 检测肿瘤新生抗原多肽的方法和装置
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
JP2023521662A (ja) 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
WO2021205027A1 (en) 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
KR20230009426A (ko) * 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
EP4149952A1 (en) * 2020-05-12 2023-03-22 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
US20230210968A1 (en) 2020-06-11 2023-07-06 Massachusetts Institute Of Technology Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
JP2023539056A (ja) 2020-08-13 2023-09-13 ビオンテック ユーエス インコーポレイテッド Ｔ細胞を製造する組成物および方法
US20230323431A1 (en) * 2020-08-31 2023-10-12 World Biotech Regenerative Medical Group Limited Personalized Immunogenic Compositions and Methods for Producing and Using Same
KR102552632B1 (ko) * 2020-11-06 2023-07-06 사회복지법인 삼성생명공익재단 중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
JP2024512462A (ja) * 2021-03-15 2024-03-19 アマゾン テクノロジーズ インコーポレイテッド 不均一な悪性腫瘍についての腫瘍ワクチン抗原カバレッジを最適化するための方法
US20240240259A1 (en) * 2021-03-26 2024-07-18 The Translational Genomics Research Institute Methods and compounds for neoantigen vaccines
BR112023022485A2 (pt) 2021-04-30 2024-01-09 Centre Hospitalier Univ Vaudois Chuv Expansão de linfócitos em um único recipiente
EP4346884A1 (en) * 2021-05-27 2024-04-10 Amazon Technologies, Inc. Multicomponent chemical composition of a peptide-based neoantigen vaccine
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CN115772564B (zh) * 2021-09-08 2023-08-18 广州市基准医疗有限责任公司 用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
EP4419716A1 (en) * 2021-10-21 2024-08-28 CureVac Netherlands B.V. Cancer neoantigens
CN116287158A (zh) * 2021-12-08 2023-06-23 初源海生物科技(深圳)有限公司 一种新抗原鉴定和疗效预测方法
EP4493212A1 (en) 2022-03-14 2025-01-22 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles
AU2023372974A1 (en) 2022-11-02 2025-06-12 Centre Hospitalier Universitaire Vaudois (Chuv) Expansion of lymphocytes
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
EP4474016A1 (en) 2023-06-07 2024-12-11 Julius-Maximilians-Universität Würzburg Strategies to target extracellularly accessible ras protein
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2026097062A1 (en) 2024-11-04 2026-05-07 Dana-Farber Cancer Institute, Inc. Genomic profiling of cells to monitor minimum residual disease
WO2026159255A1 (en) 2025-01-24 2026-07-30 BioNTech SE Technologies for mutation detection using tumor modeling and feedback

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US221332A (en) 1879-11-04 Improvement in fire-escapes
US911A (en) 1838-09-12 Mode of fastening bedsteabs
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US5589406A (en) 1993-07-30 1996-12-31 Ag Technology Co., Ltd. Method of making TFT display
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CN1367830A (zh) * 1998-10-05 2002-09-04 路德维哥癌症研究院 癌症相关抗原及其应用
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
KR100773109B1 (ko) * 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
EP1189624A4 (en) * 1999-06-29 2005-02-23 Epimmune Inc Hla binding peptides and their uses
JP2003523365A (ja) * 2000-01-28 2003-08-05 スタテンズ セーラム インスティテュート Ｈｉｖ感染の診断及びコントロールのためのｈｉｖペプチド及びそれをエンコードする核酸
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
WO2003022995A2 (en) * 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
ATE519115T1 (de) 2002-06-13 2011-08-15 Merck Patent Gmbh Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation
SI1620456T1 (sl) * 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US20070112754A1 (en) 2005-11-15 2007-05-17 Honeywell International Inc. Method and apparatus for identifying data of interest in a database
JP2009532664A (ja) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN105664147A (zh) 2007-02-07 2016-06-15 日本电气株式会社 用于癌症的治疗剂
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
ES2537323T3 (es) * 2007-08-20 2015-06-05 Oncotherapy Science, Inc. Péptido CDCA1 y agente farmacéutico que lo comprende
AU2008345036A1 (en) 2007-12-28 2009-07-09 John Wayne Cancer Institute Use of methylation status of MINT loci and tumor-related genes as a marker for melanoma and breast cancer
WO2009102909A2 (en) * 2008-02-15 2009-08-20 Board Of Regents, The University Of Texas System Anti-cancer vaccines
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
US8369279B2 (en) 2010-03-10 2013-02-05 Broadcom Corporation Method and system for iterative multiple frequency hypothesis testing with cell-ID detection in an E-UTRA/LTE UE receiver
EP2509583B1 (en) 2009-12-10 2019-05-15 Merck Patent GmbH Pharmaceutical composition comprising oligopeptides, preferably cilengitide
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
CN103221042B (zh) 2010-06-02 2016-02-10 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
WO2012095639A2 (en) 2011-01-14 2012-07-19 Genefirst Limited Methods, compositions, and kits for determing the presence/absence of a varian nucleic acid sequence
EP2744912B1 (en) 2011-08-18 2016-11-02 Nestec S.A. Compositions and methods for detecting allelic variants
AU2013221642A1 (en) 2012-02-15 2014-09-25 Janssen Diagnostics, Llc Highly sensitive method for detecting low frequency mutations
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US10176294B2 (en) 2013-03-15 2019-01-08 The Broad Institute, Inc. Accurate typing of HLA through exome sequencing
US10690658B2 (en) 2014-06-05 2020-06-23 Aimm Therapeutics B.V. Means and methods for determining T cell recognition
SI3198026T1 (sl) 2014-08-07 2020-02-28 Pharmassist Ltd Metoda za analiziranje DNA PIK3CA mutantnega statusa v vzorcu
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
WO2016183042A1 (en) 2015-05-10 2016-11-17 Quandx Inc. Ultra sensitive probes for detection of nucleic acid
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法

Also Published As

Publication number Publication date
WO2011143656A3 (en) 2012-08-23
JP7801134B2 (ja) 2026-01-16
KR20130119845A (ko) 2013-11-01
US20160008447A1 (en) 2016-01-14
KR102315754B1 (ko) 2021-10-22
JP7008049B2 (ja) 2022-02-10
JP6943545B2 (ja) 2021-10-06
EP3023788B1 (en) 2020-02-12
US20160331822A1 (en) 2016-11-17
EP3699266A1 (en) 2020-08-26
WO2011143656A2 (en) 2011-11-17
JP2019135494A (ja) 2019-08-15
US20110293637A1 (en) 2011-12-01
PT3023788T (pt) 2020-05-18
ES2788863T3 (es) 2020-10-23
CA3197245A1 (en) 2011-11-17
CN103180730B (zh) 2016-03-02
CA2797868C (en) 2023-06-20
US20180055922A1 (en) 2018-03-01
JP5948319B2 (ja) 2016-07-06
EP2569633A4 (en) 2014-05-14
KR102095670B1 (ko) 2020-03-31
AU2011252795A1 (en) 2012-11-08
HUE049886T2 (hu) 2020-10-28
EP2569633A2 (en) 2013-03-20
ES3038392T3 (en) 2025-10-13
EP4623996A2 (en) 2025-10-01
EP3023788A1 (en) 2016-05-25
EP4623996A3 (en) 2025-12-31
JP2022044632A (ja) 2022-03-17
KR102447139B1 (ko) 2022-09-23
KR20180105743A (ko) 2018-09-28
CN103180730A (zh) 2013-06-26
PL3023788T3 (pl) 2020-07-27
EP3699266B1 (en) 2025-07-02
JP2013530943A (ja) 2013-08-01
JP2016156828A (ja) 2016-09-01
US20200016251A1 (en) 2020-01-16
US20190060432A1 (en) 2019-02-28
BR122021014039B1 (pt) 2021-12-14
CN105648056A (zh) 2016-06-08
EP2569633B1 (en) 2016-02-10
AU2011252795B2 (en) 2015-09-03
KR102017898B1 (ko) 2019-09-04
KR20210129254A (ko) 2021-10-27
US10426824B1 (en) 2019-10-01
JP2024045573A (ja) 2024-04-02
BR112012029066A2 (pt) 2020-09-01
CA2797868A1 (en) 2011-11-17
KR20190133281A (ko) 2019-12-02
US20200069783A1 (en) 2020-03-05
ES2564841T3 (es) 2016-03-29
US9115402B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
HUE049886T2 (hu) Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
HUE041958T2 (hu) 4-IBB-t kötõ molekulák
PL2598531T3 (pl) Sposoby i kompozycje do terapii nowotworu wątroby
PT2593094T (pt) Composição aquosa contendo bromexina
EP2604655A4 (en) HARDENING COMPOSITION
EP2598946A4 (en) POLYMERIZABLE COMPOSITION
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
PT2585437E (pt) Compostos de tioacetato, composições e métodos de uso
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
BR112012031667A2 (pt) composição
SMT201500148B (it) Composizioni per uso nel trattamento di infezioni virali
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK3257890T3 (da) Tværbindelig sammensætning
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BR112012032683A2 (pt) composição
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
EP2636704A4 (en) FILM FORMING COMPOSITION
LT2865271T (lt) Pagerinta kompozicija
FR2955770B1 (fr) Composition cosmetique.
EP2559720A4 (en) NETWORKED COMPOSITION
EP2613344A4 (en) POLISHING COMPOSITION
FR2957252B1 (fr) Composition cosmetique